tiprankstipranks
The Fly

Scilex enters binding term sheet for joint venture with IPMC

Scilex enters binding term sheet for joint venture with IPMC

Scilex (SCLX) Holding and IPMC Company announced a binding term sheet to create a commercial joint venture, Scilex Bio, to develop and commercialize a next-generation reversible MAO-B Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer’s disease. “We are thrilled to partner with IPMC and BOIC to advance KDS2010, a promising oral therapy targeting some of the most pressing global health challenges, including obesity and neurodegenerative diseases, which affect over a billion people globally. By leveraging IPMC’s groundbreaking work on KDS2010 and Scilex’s strengths in development and commercialization, we believe this novel oral therapy may redefine treatment standards, offering a safer and more convenient solution for patients with obesity and other CNS diseases,” said Jaisim Shah, President and Chief Executive Officer of Scilex.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com